

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/843,941	0	4/30/2001	James F. Hemerick	6530.0278	8636	
22852	7590	10/11/2002				
	•	ERSON, FARAE	EXAMINER			
DUNNER L 1300 I STRI	EET, NW		THALER, MICHAEL H			
WASHINGTON, DC 20006				ART UNIT	PAPER NUMBER	
				3731		
				DATE MAILED: 10/11/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.



S.M.

Office Action Summary

Application No. 09/843,941

Examiner

Applicant(s)

Art Unit

Michael Thaler

3731

Hemerick et al.

	The MAILING DATE of this communication appears of	on the cover she	et with t	the correspondence address				
	for Reply	TO EVRIRE	2	MONTH(S) EDOM				
	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.							
- Extens	sions of time may be available under the provisions of 37 CFR 1.136 (a). In n	no event, however, ma	ay a reply b	e timely filed after SIX (6) MONTHS from the				
· If the r	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within the	e statutory minimum c	of thirty (30	)) days will be considered timely.				
- If NO p - Failure	period for reply is specified above, the maximum statutory period will apply are to reply within the set or extended period for reply will, by statute, cause the	nd will expire SIX (6) Notes to be application to become	MONTHS from ABANDO	om the mailing date of this communication.  DNED (35 U.S.C. § 133).				
	uply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nis communication, eve	en if timely	filed, may reduce any				
Status								
1) 🗆	Responsive to communication(s) filed on			•				
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This acti	ion is non-final.						
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex par							
Disposi	tion of Claims			· I				
4) 💢	Claim(s) <u>1-46</u>			is/are pending in the application.				
4	4a) Of the above, claim(s)			is/are withdrawn from consideration.				
	Claim(s)							
6) 💢	Claim(s) <u>1-46</u>			is/are rejected.				
7) 🗆	Claim(s)			is/are objected to.				
8) 🗆	Claims	are	subject	to restriction and/or election requirement.				
Applica	ation Papers							
9) 🗆	The specification is objected to by the Examiner.							
10)	The drawing(s) filed on is/are	a) accepter	d or b)[	$\sqsupset$ objected to by the Examiner.				
	Applicant may not request that any objection to the di							
11)								
	If approved, corrected drawings are required in reply t							
12)	The oath or declaration is objected to by the Examin	ner.						
Priority	under 35 U.S.C. §§ 119 and 120							
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) [	☐ All b) ☐ Some* c) ☐ None of:							
	1. $\square$ Certified copies of the priority documents have	e been received	i.					
	2. $\square$ Certified copies of the priority documents have	e been received	qqA ni t	lication No				
	3. Copies of the certified copies of the priority do application from the International Burea	ocuments have au (PCT Rule 1	been re 7.2(a)).	ceived in this National Stage				
*S	ee the attached detailed Office action for a list of the			eceived.				
14)	Acknowledgement is made of a claim for domestic	priority under 3	35 U.S.(	C. § 119(e).				
a) [	The translation of the foreign language provisional	I application ha	s been r	received.				
15)	Acknowledgement is made of a claim for domestic	priority under 3	35 U.S.C	C. §§ 120 and/or 121.				
Attachm	ent(s)	_						
1) X No	otice of References Cited (PTO-892)	<u> </u>		0-413) Paper No(s)				
_	otice of Draftsperson's Patent Drawing Review (PTO-948)	_	rmal Patent	t Application (PTO-152)				
3) 🔲 Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Dther:						

Application/Control Number: 09/843,941

Art Unit: 3731

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Winston et al. (5,306,294). Winston et al. show outer tubular structure 20, inner tubular structure 12, stent accommodating area (just distal to flange 14) and external tubular structure contact area (flange 14) which obviously slides against the interior surface of the outer tubular structure since the they are shown as contacting one another in figures 1, 2 and 4. As to claim 2, using Pellethane as the material for the inner tubular structure would have been obvious since it is well known as a desirable material for this use as indicated on page 2, lines 8-10 of applicant's specification. As to claims 3-4, note the plurality of external tubular structure contact areas 14 in figure 4 of Winston et al. As to claim 5, making the Winston et al. inner tubular structure of increasing durometer from the distal end to the proximal end, in order to enable it to flex more easily at its distal end as it traverses tortuous blood vessels would have been obvious since it is well known to so construct catheters and other Application/Control Number: 09/843,941 Page 3

Art Unit: 3731

devices inserted within blood vessels for this reason. As to claim 35, retracting the Winston et al. stent back into the outer tubular structure and then repositioning the stent delivery system when it is determined that the stent is not initially properly positioned would have been obvious since it is well known in this art to so retract and reposition stents for this reason.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Thaler whose telephone number is (703) 308-2981. The examiner can normally be reached Monday to Friday.

mht October 8, 2002 FAX (703) 305-3590 MICHAEL THALER PRIMARY EXAMINER ART UNIT 3731